Dis-organizing centrosomal clusters: Specific cancer therapy for a generic spread?

Current Medicinal Chemistry

Volumn 22, Issue 6, 2015, Pages 685-694

  Bhakta Guha, D ^a   Saeed, M E M ^b   Greten, H J ^c,d   Efferth, T ^b  

^a SASTRA UNIVERSITY   (India)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF PORTO   (Portugal)

^d Heidelberg School of Chinese Medicine   (Germany)

Author keywords

Cancer; Centrosomal clustering; Multipolar spindle inducers; Natural products; Supernumerary centrosomes

Indexed keywords

ANTINEOPLASTIC AGENT; CCC 1 01; CENTROSOMAL CLUSTERING INHIBITOR; CW 069; DEMECOLCINE; EM 011; GAMMA TUBULIN; GRISEOFULVIN; INDOQUINOLINE; LAROTAXEL; MICROTUBULE ASSOCIATED PROTEIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NATURAL PRODUCT; NOCODAZOLE; NUCLEOPHOSMIN; PACLITAXEL; PHENANTHRIDINE DERIVATIVE; PHTHALIMIDE DERIVATIVE; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINOLIZINE DERIVATIVE; SEPARASE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; BIOLOGICAL PRODUCT;

ANEUPLOIDY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DEATH; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CENTROSOMAL CLUSTERING; CENTROSOME; CHROMOSOMAL INSTABILITY; DAUGHTER CELL; DRUG EFFICACY; HUMAN; HYDROGEN BOND; INHIBITION CONSTANT; MARINE SPECIES; MICROTUBULE ASSEMBLY; MITOSIS SPINDLE; MOLECULAR DOCKING; NONHUMAN; PROTEIN SECONDARY STRUCTURE; SUPERNUMERARY CHROMOSOME; ANIMAL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY;

ANIMALS; BIOLOGICAL PRODUCTS; CENTROSOME; HUMANS; NEOPLASMS;

EID: 84931273728     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666141212114529     Document Type: Article

References (93)

1. http://www.who.int/topics/cancer/en/index.html.
2. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859), 2095-2128.
3. Bray, F.; Ren, J.S.; Masuyer, E.; Ferlay, J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer, 2013, 132(5), 1133-1145.
4. Hussain, S.A.; Sullivan, R. Cancer Control in Bangladesh. Jpn. J. Clin. Oncol., 2013, 43(12), 1159-1169.
5. Bornens, M. The centrosome in cells and organisms. Science, 2012, 335(6067), 422-426.
6. Gergely, F.; Basto, R. Multiple centrosomes: Together they stand, divided they fall. Genes Dev., 2008, 22(17), 2291-2296.
7. Musch A. Microtubule organization and function in epithelial cells. Traffic, 2004, 5, 1-9.
8. Scliwa, M.; Honer, B. Microtubules, centrosomes and intermediate filaments in directed cell movement. Trends Cell. Biol., 1993, 3, 377-380.
9. Wakida, N.M.; Botvinick, E.L.; Lin, J.; Berns, M.W. An intact centrosome is required for the maintenance of polarization during directional cell migration. PLoS One, 2010, 5, e15462.
10. Rebollo, E.; Sampaio, P.; Januschke, J.; Llamazares, S.; Varmark, H.; González, C. Functionally unequal centrosomes drive spindle orientation in asymmetrically dividing Drosophila neural stem cells. Dev. Cell., 2007, 12, 467-474.
11. D'Assoro, A.B.; Lingle, W.L.; Salisbury, J.L. Centrosome amplification and the development of cancer. Oncogene, 2002, 21, 6146-6153.
12. Hinchcliffe, E.H.; Sluder, G. Two for two: Cdk2 and its role in centrosome doubling. Oncogene, 2002, 21(40), 6154-6160.
13. Zyss, D.; Gergely, F. Centrosome function in cancer: guilty or innocent? Trends Cell Biol., 2009, 19(7), 334-346.
14. Tsou, M-F.B.; Stearns, T. Controlling centrosome number: licenses and blocks. Curr. Opin. Cell. Biol., 2006, 18, 74-78.
15. Barrera, J.A.; Kao, L-o.; Hammer, R.E.; Seemann, J.; Fuchs, J.L.; Megraw, T.L. CDK5RAP2 Regulates Centriole Engagement and Cohesion in Mice. Dev. Cell, 2010, 18(6), 913-926.
16. Fisk, H.A.; Mattison, C.P.; Winey, M. Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression. Proc. Natl. Acad. Sci. USA, 2003, 100(25), 14875-14880.
17. Wang, X.; Yang, Y.; Duan, Q.; Jiang, N.; Huang, Y.; Darzynkiewicz, Z.; Dai, W. sSgo1, a major splice variant of Sgo1, functions in centriole cohesion where it is regulated by Plk1. Dev. Cell., 2008, 14, 331-341.
18. Hornig, N.C.; Uhlmann, F. Preferential cleavage of chromatinbound cohesin after targeted phosphorylation by Polo-like kinase. EMBO J., 2004, 23, 3144-3153.
19. Tsou, M.F.; Wang, W.J.; George, K.A.; Uryu, K.; Stearns, T.; Jallepalli, P.V. Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev. Cell, 2009, 17(3), 344-354.
20. Hemerly, A.S.; Prasanth, S.G.; Siddiqui, K.; Stillman, B. Orc1 controls centriole and centrosome copy number in human cells. Science, 2009, 323(5915), 789-793.
21. Barr, A.R.; Kilmartin, J.V.; Gergely, F. CDK5RAP2 functions in centrosome to spindle pole attachment and DNA damage response. J. Cell. Biol., 2010, 189(1), 23-39.
22. Wang, H.; Takenaka, K.; Nakanishi, A.; Miki, Y. BRCA2 and Nucleophosmin coregulate centrosome amplification and form a complex with the rho effector kinase ROCK2. Cancer Res., 2011, 71(1), 68-77.
23. Brinkley, B.R. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell. Biol., 2001, 11, 18-21.
24. Ganem, N.J.; Godinho, S.A.; Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature, 2009, 460, 278-282.
25. Kops, G.J.; Foltz, D.R.; Cleveland, D.W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl. Acad. Sci. USA., 2004, 101, 8699-8704.
26. Weaver, B.A.; Silk, A.D.; Montagna, C.; Verdier-Pinard, P.; Cleveland, D.W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell., 2007, 11, 25-36.
27. Basto, R.; Brunk, K.; Vinadogrova, T.; Peel, N.; Franz, A.; Khodjakov, A.; Raff, J.W. Centrosome amplification can initiate tumorigenesis in flies. Cell, 2008, 133, 1032-1042.
28. Krämer, A.; Maier, B.; Bartek, J. Centrosome clustering and chromosomal (in)stability: A matter of life and death. Mol. Oncol., 2011, 5, 324-335.
29. Ring, D.; Hubble, R.; Kirschner, M. Mitosis in a cell with multiple centrioles. J. Cell Biol., 1982, 94, 549-556.
30. Nigg, E.A. Centrosome aberrations: cause or consequence of cancer progression? Nat. Rev. Cancer, 2002, 2, 815-825.
31. Leber, B.; Maier, B.; Fuchs, F.; Chi, J.; Riffel, P.; Anderhub, S.; Wagner, L.; Ho, A.D.; Salisbury, J.L.; Boutros, M.; Krämer, A. Proteins required for centrosome clustering in cancer cells. Sci. Transl. Med., 2010, 2(33), 1-12.
32. Quintyne, N.J.; Reing, J.E.; Hoffelder, D.R.; Gollin, S.M.; Saunders, W.S. Spindle multipolarity is prevented by centrosomal clustering. Science, 2005, 307(5706), 127-129.
33. Kwon, M.; Godinho, S.A.; Chandhok, N.S.; Ganem, N.J.; Azioune, A.; Thery, M.; Pellman, D. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev., 2008, 22, 2189-2203.
34. Xu, F.L.; Saunders, W.S. Actin and microtubules: working together to control spindle polarity. Cancer Cell., 2008, 14(3), 197-199.
35. Korzeniewski, N.; Hohenfellner, M.; Duensing, S. The centrosome as potential target for cancer therapy and prevention. Expert Opin. Ther. Targets, 2013, 17(1), 43-52.
36. Silkworth, W.T.; Nardi, I.K.; Scholl, L.M.; Cimini, D. Multipolar spindle pole coalescence is a major source of kinetochore misattachment and chromosome mis-segregation in cancer cells. PLoS One, 2009, 4, 6564.
37. Mayer, T.U.; Kapoor, T.M.; Haggarty, S.J.; King, R.W.; Schreiber, S.L.; Mitchison, T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotypebased screen. Science, 1999, 286, 971-974.
38. Ogden, A.; Rida, P.C.G.; Aneja, R. Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy. Cell Death Differ., 2012, 19, 1255-1267.
39. Cooper, G.M.; Hausman, R.E. Microtubules. The Cell: A Molecular Approach. 5th edition. Sinauer Associates; 2000 (504-520).
40. Liu, D.; Vader, G.; Vromans, M.J.M.; Lampson, M.A.; Lens, S.M.A. Sensing chromosome bi-orientation by spatial separation of aurora B kinase from kinetochore substrates. Science, 2009, 323, 1350-1353.
41. Ruchaud, S.; Carmena, M.; Earnshaw, W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol., 2007, 8, 798-812.
42. Wei, R.R.; Al-Bassam, J.; Harrison, S.C. The Ndc80/HEC1 complex is a contact point for kinetochore-microtubule attachment. Nat. Struct. Mol. Biol., 2007, 14, 54-59.
43. Vaughan, K.T. TIP maker and TIP marker; EB1 as a master controller of microtubule plus ends. J. Cell Biol., 2005, 171, 197-200.
44. Boyarchuk, Y.; Salic, A.; Dasso, M.; Arnaoutov, A. Bub1 is essential for assembly of the functional inner centromere. J. Cell Biol., 2007, 176, 919-928.
45. Kelly, A.E.; Ghenoiu, C.; Xue, J.Z.; Zierhut, C.; Kimura, H.; Funabiki, H. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science., 2010, 330(6001), 235-239.
46. Dai, J.; Kataneva, A.V.; Higgins, J.M.G. Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis requires chromosome cohesion. J. Cell Sci., 2009, 122, 4168-4176.
47. Hori, T.; Amano, M.; Suzuki, A.; Backer, C.B.; Welburn J.P.; Dong, Y.; McEwen, B.F.; Shang, W.H.; Suzuki, E.; Okawa, K.; Cheeseman, I.M.; Fukagawa, T. CCAN makes multiple contacts with centromeric DNA to provide distinct pathways to the outer kinetochore. Cell, 2008, 135, 1039-1052.
48. Schmitz, J.; Watrin, E.; Lenart, P.; Mechtler, K.; Peters, J.M. Sororin is required for stable binding of cohesin to chromatin and for sister chromatid cohesion in interphase. Curr. Biol., 2007, 17, 630-636.
49. Koffa, M.D.; Casanova, C.M.; Santarella, R.; Kocher, T.; Wilm, M.; Mattaj, I.W. HURP is part of a Ran-dependent complex involved in spindle formation. Curr. Biol., 2006, 16, 743-754.
50. Harvey, A.L.; Cree, I.A. High-throughput screening of natural products for cancer therapy. Planta Med., 2010, 76, 1080-1086.
51. Farnsworth, N.R. Ethnobotany and the Search for New Drugs. Wiley Willett WC. Diet and health: what should we eat. Science, 1994, 264(5158), 532-537.
52. Greve, H.; Schupp, P.J.; Eguerva, E.; Kehraus, S.; Kelter, G.; Maier, A.; Fiebig, H-H.; König, G.M. Apralactone A and a new stereochemical class of cuvularians from the marine-derived fungus Curvularia sp. Eur. J. Org. Chem., 2008, 2008(30), doi:10.1002/ejoc.200800522.
53. Okouneva, T.; Hill, B.T.; Wilson, L.; Jordan, M.A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther., 2003, 2, 427-436.
54. Sawadogo, W.R.; Schumacher, M.; Teiten, M.H.; Cerella, C.; Dicato, M.; Diederich, M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011. Molecules., 2013, 18, 3641-3673.
55. Tuxen, M.K.; Hansen, S.W. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat. Rev., 1994, 20(2), 191-214.
56. Dieras VC, Limantani SA, Lortholary A, et al. A multicentre, non randomized phase II study with RPR 109881A in metastatic breast cancer (MBC) patients (pts). ASCO meeting. 2004; abstract no. 565.
57. Pivot, X.; Koralewski, P.; Hidalgo, J.L.; Chan, A.; Gonçalves, A.; Schwartsmann, G.; Assadourian, S.; Lotz, J.P. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol., 2008, 19(9), 1547-1552.
58. Yamamoto, N.; Boku, N.; Minami, H. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer Chemother. Pharmacol., 2009, 65(1), 129-136.
59. Greenberger, L.M.; Sampath, D. Resistance To Taxanes. Cancer Drug Discovery and Development: Cancer Drug Resistance Edited by: B. Teicher Humana Press Inc., Totowa, NJ. 2007. 329-357.
60. Ye, K.; Ke, Y.; Keshava, N.; Shanks, J.; Kapp, J.A.; Tekmal, R.R.; Petros, J.; Joshi, H.C. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. USA., 1998, 95(4), 1601-1606.
61. Zuckerberg, C.; Solari, A.J. Centriolar changes induced by vinblastine sulphate in the seminiferous epithelium of the mouse. Exp. Cell Res., 1973, 76(2), 470-475.
62. Raskin, I.; Ribnicky, D.M.; Komarnytsky, S.; Ilic, N.; Poulev, A.; Borisjuk, N.; Brinker, A.; Moreno, D.A.; Ripoll, C.; Yakoby, N.; O'Neal, J.M.; Cornwell, T.; Pastor, I.; Fridlender, B. Plants and human health in the twenty-first century. Trends Biotechnol., 2002, 20(12), 522-532.
63. Satish, S.; Raghavendra, M.P.; Raveesha, K.A. Evaluation of the antibacterial potential of some plants against human pathogenic bacteria. Adv. Biol. Res., 2008, 2(3-4), 44-48.
64. Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
65. Cassady, J.M.; Douros, J.D. (Eds.). Anticancer Agents Based on Natural Product Models. Academic Press, New York, 1980.
66. Lyseng-Williamson, K.A.; Fenton, C. Docetaxel: A review of its use in metastatic breast cancer. Drugs, 2005, 65(17), 2513-2531.
67. Gidding, C.E.M.; Kellie, S.J.; Kamps, W.A.; de Graaf, S.S.N. Vincristine revisited. Crit. Rev. Oncol. Hematol., 1999, 29(3), 267-287.
68. Sertel, S.; Fu, Y.; Zu, Y.; Rebacz, B.; Konkimalla, B.; Plinkert, P.K.; Krämer, A.; Gertsch, J.; Efferth, T. Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem. Pharmacol., 2011, 81, 723-735.
69. Hamel, E.; Lin, C.M. Interactions of combretastatin, a new plantderived antimitotic agent, with tubulin. Biochem. Pharmacol., 1983, 32(24), 3864-3867.
70. Efferth, T.; Wink, M. Chemical-biology of natural products from medicinal plants for cancer therapy. In: M. Alaoui-Jamali (Ed.) Alternative complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs. Springer, New York, USA, 2010, 22, 557-582.
71. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75, 311-335.
72. Segraves, N.L.; Lopez, S.; Johnson, T.A.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Structures and cytotoxicities of fascaplysin and related alkaloids from two marine phyla-Fascaplysinopsis sponges and Didemnum tunicates. Tetrahedron Lett., 2003, 44, 3471-3475.
73. Segraves, N.L.; Robinson, S.J.; Garcia, D.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Comparison of fascaplysin and related alkaloids: A study of structures, cytotoxicities, and sources. J. Nat. Prod., 2004, 67, 783-792.
74. Yan, X.; Chen, H.; Lu, X.; Wang, F.; Xu, W.; Jin, H.; Zhu, P. Fascaplysin exert anti-tumor effects through apoptotic and antiangiogenesis pathways in sarcoma mice model. Eur. J. Pharm. Sci., 2011, 43, 251-259.
75. Bai, R.; Petit, G.R.; Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol., 1990, 39(12), 1941-1949.
76. Zheng, L.; Wang, Y.; Sheng, J.; Wang, F.; Zheng, Y.; Lin, X.; Sun, M. Antitumor peptides from marine organisms. Mar. Drugs, 2011, 9(10), 1840-1859.
77. Lachia, M.; Moody, C.J. The synthetic challenge of diazonamide A, a macrocyclic indole bis-oxazole marine natural product. Nat. Prod. Rep., 2008, 25, 227-253.
78. Liu, S.; Cui, Y.M.; Nan, F.J. Total synthesis of the originally proposed and revised structures of scleritodermin A. Org. Lett., 2008, 10, 3765-3768.
79. O'Toole, E.; Greenan, G.; Lange, K.I.; Srayko, M.; Mü ller-Reichert, T. The role of tubulin in centrosomal microtubule organization. PLoS ONE, 2012, 7(1), e 29795.
80. Nguyen, C.L.; Eichwald, C.; Nibert, M.L.; Münger, K. Human Papillomavirus type 16 E7 oncoprotein associates with the centrosomal component tubulin. J. Virol., 2007, 81(24), 13533-13543.
81. Hutchinson, L.; Kirk, R. High drug attrition rates-where are we going wrong? Nature Rev. Clin. Oncol., 2011, 8, 189-190.
82. Rebacz, B.; Larsen, T.O.; Clausen, M.H.; Rønnest, M.H.; Löffler, H.; Ho, A.D.; Krämer, A. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res., 2007, 67(13), 6342-6350.
83. Rønnest, M.H.; Rebacz, B.; Markworth, L.; Terp, A.H.; Larsen, T.O.; Krämer, A.; Clausen, M.H. Synthesis and structure-activity relationship of griseofulvin analogues as inhibitors of centrosomal clustering in cancer cells. J. Med. Chem., 2009, 52(10), 3342-3347.
84. Fielding, A.B.; Lim, S.; Montgomery, K.; Dobreva, I.; Dedhar, S. A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene, 2011, 30(5), 521-534.
85. Karna, P.; Rida, P.C.; Pannu, V.; Gupta, K.K.; Dalton, W.B.; Joshi, H.; Yang, V.W.; Zhou, J.; Aneja, R. A novel microtubulemodulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death Differ., 2011, 18(4), 632-644.
86. Zacharaki, P.; Stephanou, G.; Demopoulos, N.A. Comparison of the aneugenic properties of nocodazole, paclitaxel and griseofulvin in vitro. Centrosome defects and alterations in protein expression profiles. J. Appl. Toxicol., 2013, 33(9), 869-879.
87. Pries, V.; Khedkar, V.; Menninger, S.; Bruss, H.; Bird, A.W.; Maliga, Z.; Brockmeyer, A.; Janning, P.; Hyman, A.; Grimme, S.; Schürmann, M.; Preut, H.; Hübel, K.; Ziegler, S.; Kumar, K.; Waldmann, H. Natural product-inspired cascade synthesis yields modulators of centrosome integrity. Nat. Chem. Biol., 2011, 8(2), 179-184.
88. Raab, M.S.; Breitkreutz, I.; Anderhub, S.; Rønnest, M.H.; Leber, B.; Larsen, T.O.; Weiz, L.; Konotop, G.; Hayden, P.J.; Podar, K.; Fruehauf, J.; Nissen, F.; Mier, W.; Haberkorn, U.; Ho, A.D.; Goldschmidt, H.; Anderson, K.C.; Clausen, M.H.; Krämer, A. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res., 2012, 72(20), 5374-5385.
89. Shiheido, H.; Terada, F.; Tabata, N.; Hayakawa, I.; Matsumura, N.; Takashima, H.; Ogawa, Y.; Du W.; Yamada, T.; Shoji, M.; Sugai, T.; Doi, N.; Iijima S.; Hattori, Y.; Yanagawa, H. A phthalidimide derivative that inhibits centrosomal clustering is effective on multiple myeloma. PLoS One, 2012, 7(6), e38878.
90. Castiel, A.; Visochek, L.; Mittelman, L.; Dantzer, F.; Izraeli, S.; Cohen-Armon, M. A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer, 2011, 11, 412.
91. Watts, C.A.; Richards, F.M.; Bender, A.; Bond, P.J.; Korb, O.; Kern, O.; Riddick, M.; Owen, P.; Myers, R.M.; Raff, J.; Gergely, F.; Jodrell, D.I.; Ley, S.V. Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem. Biol., 2013, 20, 1399-1410.
92. Kawamura, E.; Fielding, A.B.; Kannan, N.; Balgi, A.; Eaves, C.J.; Roberge, M.; Dedhar, S. Identification of novel small molecule inhibitors of centrosome clustering in cancer cells. Oncotarget, 2013, 4(10), 1763-1776.
93. Zhao, G.D.; Wan, R.Z.; Liu, Z.P. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds. Curr. Med. Chem., 2014, 21(23), 2691-2701.